New video just out on youtube for the presentation that Bill gave at the recent Sachs Neuroscience Innovation Forum (link below).
He seemed a bit rusty, but generally a good preso.
Couple of key points I took out of it....
- the final DSMB safety analysis will be “in a month or two”
- confident that the efficacy design is appropriate based on the first DSMB analysis
- full results reading out in “May/June”
- they’ve been approached by others for additional indications using xanamem
- current target market for mild Alzheimer’s is US$7.5B based on 1.5m patients. Bill alludes to the upside if you include Prodromol and At Risk markets which have numbers of 4m and 25m, respectively. Even penetrating only 10% of those markets would be massive given that there are almost 20 times more potential users than mild AD.
- Forums
- ASX - By Stock
- ACW
- Sachs Forum Presentation Video
Sachs Forum Presentation Video
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
Add ACW (ASX) to my watchlist
|
|||||
Last
7.1¢ |
Change
0.003(4.41%) |
Mkt cap ! $192.5M |
Open | High | Low | Value | Volume |
6.6¢ | 7.2¢ | 6.5¢ | $352.6K | 5.156M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 7.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.1¢ | 205031 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.070 |
2 | 57260 | 0.069 |
4 | 197960 | 0.068 |
1 | 7477 | 0.067 |
2 | 113636 | 0.066 |
Price($) | Vol. | No. |
---|---|---|
0.071 | 205031 | 1 |
0.072 | 726000 | 3 |
0.074 | 50000 | 1 |
0.076 | 449940 | 1 |
0.077 | 55000 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |